Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple myeloma: A randomized phase 2 trial by the nordic myeloma study group

Henrik Gregersen, Valdas Peceliunas, Kari Remes, Fredrik H. Schjesvold, Niels Abildgaard, Hareth Nahi, N. F. Andersen, Annette Juul Vangsted, Tobias Wirenfeldt Klausen, Carsten Helleberg, K. Carlson, Ulf Frølund, Per Axelsson, Olga Stromberg, C Blimark, Olle Linder, Galina Tsykunova, Anders Waage, Markus Hansson, N. Guldbrandsen

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
ArtikelnummerS1602
TidsskriftHemaSphere
Vol/bind3
Sider (fra-til)737-738
StatusUdgivet - jun. 2019
Begivenhed24th European Hematology Association Congress (EHA) - Amsterdam, Holland
Varighed: 13. jun. 201916. jun. 2019

Konference

Konference24th European Hematology Association Congress (EHA)
LandHolland
ByAmsterdam
Periode13/06/201916/06/2019

Citationsformater

Gregersen, H., Peceliunas, V., Remes, K., Schjesvold, F. H., Abildgaard, N., Nahi, H., Andersen, N. F., Vangsted, A. J., Klausen, T. W., Helleberg, C., Carlson, K., Frølund, U., Axelsson, P., Stromberg, O., Blimark, C., Linder, O., Tsykunova, G., Waage, A., Hansson, M., & Guldbrandsen, N. (2019). Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple myeloma: A randomized phase 2 trial by the nordic myeloma study group. HemaSphere, 3, 737-738. [S1602].